Objectives To assess the cost-effectiveness of nivolumab for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCLC) progressed on or after platinum-based chemotherapy using a modelled economic evaluation. Methods Both partition survival (PS) and Markov models, comprised of three health states, were adopted to evaluate the cost-effectiveness of nivolumab compared to docetaxel from an Australian healthcare system perspective with a 6-year time horizon. Reconstructed individual patient data (IPD) were derived from published Kaplan-Meier curves from the pivotal trial for overall survival (OS) and progression-free survival (PFS) using a validated algorithm. Best-fitting survival curves were selected to extrapolate the OS, PFS and post-progression survival (PPS) beyond trial duration. Expected costs and health outcomes [i.e. quality-adjusted life year (QALY), and life year (LY)] associated with each of the health states (i.e. PF, PD and dead) were accrued over the time horizon. Both deterministic and probabilistic sensitivity analyses were undertaken. Results Nivolumab was associated with both higher costs and benefits in both PS and Markov models. In particular, from the PS model, nivolumab cost an additional A$198,862/QALY and A$181,623/LY gained. The Markov model showed that nivolumab had an incremental cost-effectiveness ratio (ICER) of A$220,029/QALY and A$193,459/LY, respectively. The sensitivity analyses showed base-case results were sensitive to the extrapolation approach, duration of treatment, cost of nivolumab and time horizon modelled. Conclusions Using an often-quoted willingness-to-pay per QALY threshold in Australia (i.e. A$50,000), the treatment with nivolumab cannot be considered cost-effective. It might be funded publicly by special arrangements given unmet clinical needs for patients.
Introduction
According to the World Health Organization (WHO), lung cancer accounted for approximately 1.59 million cases of the 8.2 million cancer-related deaths reported in 2012, making it this indication on the basis that the lack of cost-effectiveness with docetaxel had not been adequately demonstrated [12] . However, the model utilised in the economic evaluation considered by PBAC is not in the public domain. Therefore, the current study is the first published modelled economic evaluation to assess the cost-effectiveness of nivolumab in treating patients with advanced or metastatic squamous NSCLC progression on or after platinum-based chemotherapy in Australia. This information will benefit clinicians and decision makers when assessing the cost-effectiveness of employing nivolumab in lung cancer treatment.
Methods

Choice of Modelling Approaches
Both Markov (as adopted in the submission to the PBAC by the manufacturer) [12] and partition survival (PS) models were used to assess the long-term economic credentials of nivolumab for patients with advanced or metastatic squamous NSCLC progression on or after platinum-based chemotherapy from the Australian healthcare system perspective. Markov and PS models are the two most common modelling approaches used to estimate long-term costs and effects in cancer research.
An advantage of developing PS models is that they utilise survival data already produced in clinical trials and avoid the necessity to estimate transition probabilities. However, it was reported that the cost-effectiveness results of using a PS model may have more of an inherent bias in favour of intervention with a disease progression advantage than a Markov model because in the PS model survival endpoints are assumed to be independent [13, 14] . In comparison, a Markov model has the benefits of maximum flexibility in terms of data source and number of health states (a feature more important for cancer treatment). In addition, it also takes the post-progression survival (PPS) into account (i.e. it requires the derivation of transition probabilities). As the two approaches would complement each other, both modelling approaches were employed in the present study.
Model Structures
Following the previous models that assessed the cost-effectiveness of interventions for NSCLC [7, 15] , a cohort model with three health states, consisting of (i) stable without progression; (ii) post-progression survival; and (iii) dead, was adopted for both PS and Markov models (see Supplementary Fig. 13 ). The health states modelled are consistent with the primary (i.e. overall survival) and secondary (including progression free survival, patient-reported outcome) endpoints of the pivotal clinical trial [16] . In brief, a total of one of the most significant causes of deaths worldwide [1] . Lung cancer is also the leading cause of death and fifth most common cancer diagnosed in Australia [2] . It is estimated that 12,741 new cases (consisting of 7212 males and 5529 females) of lung cancer will be diagnosed in 2018. Due to the timing of the diagnosis, the survival rate from lung cancer is poor. Between 2009 and 2013, individuals diagnosed with lung cancer had a 16% chance (14% for males and 19% for females) of surviving for 5 years [2] .
From a financial perspective, cancer was associated with A$895 billion total global economic loss in 2008, equivalent to 1.5% of the gross domestic product (GDP) worldwide [3] . Among these, cancers of the lung (including bronchus, trachea) conferred the largest economic burden among all tumour sites, accounting for nearly A$180 billion globally in 2008 [3] . Given the economic burden of lung cancer worldwide, its treatment is constantly a focus of clinical interest and research.
Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for around 80% of cases, while small-cell lung cancer (SCLC), which has the highest occurrence in smokers [4] and spreads more quickly than NSCLC, accounts for the remaining 20% of cases [5] . The median overall survival (OS) for patients with advanced NSCLC is only 4.9 months, with 1-and 2-year OS rates of 23% and 7%, respectively [6] . Whilst the squamous histological subtype accounts for approximately 15-25% of NSCLC, the treatment modalities for lung cancers are primarily dependent on the stages of cancer. As the majority of patients with NSCLC are diagnosed in the advanced stage (65-75% of cases presenting as locally advanced or metastatic), the aim of treatment is rarely curative but often to control the progress of the disease [7] . In particular, for patients with NSCLC whose disease progresses after firstline chemotherapy, effective options are limited. Currently in Australia docetaxel is approved and publicly funded as the second-line treatment for advanced squamous NSCLC. However, docetaxel was approved on the basis of longer survival than that with best supportive care [8] [9] [10] . Hence, there is still a significant unmet clinical need for patients with advanced squamous NSCLC in Australia.
Nivolumab is a fully human immunoglobulin G4 (lgG4) monoclonal antibody that binds to PD-1 receptors and blocks their interaction with PD-L1 and PD-L2, thereby preventing activation of the PD-1 pathway. This cellular mechanism enhances T-cell responses, resulting in increased activity of the immune system against tumour cells [11] . The Pharmaceutical Benefits Advisory Committee (PBAC) of Australia considered the use of nivolumab for the treatment of locally advanced or metastatic squamous NSCLC with progression on or after platinum-based chemotherapy in 2016. However, the PBAC deferred its decision on the listing of nivolumab in the Pharmaceutical Benefits Scheme (PBS) for 96% of the patients randomised received the assigned treatment drug (131 with nivolumab and 129 with docetaxel [16] . Therefore, the progression-free survival (PFS) and overall survival (OS) curves from this pivotal clinical trial were used to inform the PS and Markov models. Because the median follow-up in the trial was 17.2 months, it was necessary to extrapolate the observed PFS and OS beyond the duration of the trial follow-up. The method described by Guyot et al. was employed to derive the individual patient data (IPD) based on the published Kaplan-Meier survival curves [17] (a validated graphical digitiser, WebPlotDigitizer V3.9 http://aroha tgi.info/WebPl otDig itize r, was used to extract the graphic data). Briefly, an algorithm was used to map from digitalised curves back to Kaplan-Meier (KM) data by finding solutions to the inverted KM equations, based on the published information about number of events and number at risk [17] . Then parametric survival curves, including exponential, Weibull, log-logistic, log-normal, gompertz, generalised gamma (old and new parameterisation in 'flexsurv' package of R [18] ) distributions were fitted to the reconstructed IPD in order to extrapolate to a longer time horizon. The process of fitting parametric survival curves to IPD was based on guidance provided by the Decision Support Unit at the National Institute for Health and Care Excellence (NICE) [19, 20] . Briefly, the steps included: (i) testing of proportional effects assumption (i.e. the log cumulative hazard) to determine if the survival curves of nivolumab and docetaxel were parallel; (ii) then fitting the reconstructed IPD with single or separate distribution(s) depending on the conclusion of the first step; and (iii) the most appropriate fit was determined by both visual inspection and Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) goodness-of-fit statistics. The Kaplan-Meier curves built on reconstructed IPD are supplied in Supplementary  Figs. 1 and 2 . The median PFS and OS for the two treatment groups using the reconstructed IPD are summarised in Supplementary Table 1 . As the proportional hazard assumption did not hold for PFS and OS, independent parametric survival curves were fitted separately for docetaxel and nivolumab arms of the pivotal trial (log cumulative hazard and cumulative hazard for nivolumab and docetaxel are shown in Supplementary Figs. 3-6 ). Based on the criteria set above, the gompertz distribution was selected to fit the PFS data in the nivolumab arm ( Supplementary Fig. 7 ) and log-normal distribution was chosen to fit the PFS data in the docetaxel arm ( Supplementary Fig. 8 ). For the OS data, loglogistic distribution was considered appropriate to fit the OS data in both the nivolumab and docetaxel arms (Supplementary Figs. 9 and 10). Parameters of the corresponding distributions used to parameterise the fitted survival curves are shown in Supplementary Table 3 . Additionally, using the same selection criteria, second-best distribution (for PFS, generalised gamma-nivolumab, log-logistic-docetaxel; for post-progression survival, log-logistic-nivolumab, Weibull-docetaxel; for OS, generalised gamma-nivolumab, exponential-docetaxel) was selected to test the robustness of the base-case extrapolation. The goodness-of-fit statistics of fitted survival curves of tested distributions are provided in Supplementary Table 2.
PS Model
The PFS and OS curves were used to estimate the proportion of patients who survived without progression, survived after progression, and were dead at each of the follow-up time points. Specifically, the proportion of patients who were PF at a given follow-up was directly read from the PFS curve and the proportion of patients who had died at a certain follow-up was calculated as one minus the corresponding value from the OS curve. The difference in proportions between OS and PFS at a certain time point is considered as the proportion of patients who progressed over that time interval.
Markov Model
The time-dependent transition probabilities for each of the health states were derived using reconstructed IPD. In addition to the OS and PFS curves used in the PS model, the time from progressed disease to death provided an extra level of information about the number of patients transitioning from the progressed disease state to the death state over time (derived from the reconstructed IPD). Similarly, a parametric curve was fitted to the reconstructed post-progression data from the pivotal trial ( Supplementary Figs. 11 and 12 ). The changes in proportions of patients who were free of progression and survived after progression over time were then used to calculate the probability of patients transitioning from PF to PD/death, from PD to death at each cycle. The model was structured in a way that allowed the patient to transition from the PF state to the PD state and then survive or die in the remaining cycle length (Supplementary Fig. 13 ). The OS predicted by the Markov model was then compared to the OS curve generated and extrapolated from the IPD. If the predicted OS (from the Markov model) and the observed (and extrapolated, from pivotal trial) OS curves overlap each other, this suggests that the Markov model produces a reasonable estimate over time. Likewise, alternative distribution fitting the post-progression data was tested in the sensitivity analysis.
Costs
In general, all costs and resource use inputs were obtained from either publicly available sources or published health economic literature. The costs taken into consideration were: disease management costs (i.e. ongoing inpatient and outpatient care for PF and PD health states); cost of chemotherapy drug (i.e. nivolumab or docetaxel); cost of chemotherapy administration; cost of drug monitoring; and cost of treatment-related adverse events (TRAEs). If the disease progressed, it was assumed no treatment cost would be incurred. All the costs were valued in the year 2017. Since the government website-(i.e. PBS) listed price of nivolumab is for treatment of malignant melanoma, it was considered inappropriate to apply that price in the current economic evaluation. Instead, the unit cost of nivolumab was sourced from Canada [7] and the corresponding PBS price was tested in the sensitivity analysis. The detailed unit cost and resource use are provided in Table 1 . The frequency of TRAEs was taken from the pivotal trial [16] . The costs associated with treating adverse events are presented in Supplementary Table 4 .
Utilities
The utility weights were sourced from another economic evaluation of nivolumab in patients with advanced NSCLC conducted from the Canadian healthcare system perspective. Specifically, based on the trial data, the utility weights (derived from EQ-5D-5L based on Canadian tariff and completed by patients recruited in the pivotal nivolumab trial [7] ) for PF was 0.789 (95% CI 0.778-0.799) and for PD was 0.674 (95% CI 0.647-0.702) [7] . Since concern in using the EQ-5D outcome from the trial was raised by the PBAC, alternative data on the utilities associated with PF (0.799) and PD (0.702) were examined in the sensitivity analyses [12] .
The disutilities associated with TRAEs were not considered in the model since the incidence of TRAEs was generally lower in the nivolumab treatment arm compared to the docetaxel treatment arm; the omission of disutilties associated with TRAEs was unlikely to favour the nivolumab arm.
Population, Model Assumptions, Time Horizon, Cycle Length and Perspective
Australian patients diagnosed with advanced or metastatic squamous NSCLC were simulated in both the PS and Markov models. The median age of the population was defined as consistent with those recruited in the pivotal trial (i.e. median age of 63 years with the majority of patients aged younger than 65 years) [16] . A key assumption of the model was that the treatment effect would be maintained until disease progression, which is consistent with the approved product information of nivolumab [21] . Based on the extrapolated OS curves for nivolumab and docetaxel treatment groups, the base-case time horizon was set to 6 years given the proportion of patients being alive at year 6 was less than 0.04. However, varied time horizons were tested in the sensitivity analyses. As Australia has a universal cover of publicly funded health insurance (i.e. Medicare), the healthcare system perspective was taken to gauge the cost associated with treating NSCLC; a 3% discount rate was applied for costs, quality-adjusted life years (QALYs) and life years (LYs). A 4-week cycle length was adopted to accommodate the different dosing regimens of two drugs (i.e. every 2 weeks for nivolumab vs. every 3 weeks for docetaxel).
Sensitivity Analyses
A series of one-way sensitivity analyses were conducted to test the robustness of the base-case results. Where applicable, the key model parameters were varied within a particular range (based on the best available evidence or increase or decrease by 20% for costs if insufficient data to inform on the range). The results from the one-way sensitivity analyses are shown in terms of a Tornado diagram, graphing sequentially the variables with the largest impact on the cost-utility results. In addition, probabilistic sensitivity analyses (PSA) were performed to assess the overall impact of uncertainty in the model by defining distributions for the key parameters in the Markov model (i.e. variables regarding transition probabilities, utilities and costs) (Supplementary Table 5 ). 5000 iterations (i.e. second-order Monte Carlo simulations) were run to construct a mean and 95% confidence interval for the corresponding costs and benefits and the results were plotted on the cost-effectiveness plane.
Results
Base Case
In the PS model, it was found that over a 6-year time horizon, the patients treated with nivolumab were associated Table 2 ). The Markov model produced similar results to the PS model; in particular, nivolumab was again associated with higher cost (A$100,236 vs. A$22,534) , QALY (1.03 vs. 0.68) and LYs (1.32 vs. 0.91) when compared to docetaxel. The corresponding ICERs were A$220,029/QALY and A$193,459/LY. It was observed that the benefit from nivolumab treatment largely lay with the survival gain rather than the improvement in the quality of life ( Table 2 ). The Markov state probability over the entire time horizon is presented in Supplementary Fig. 14. 
Sensitivity Analyses
Deterministic Sensitivity Analyses
For the PS model, sensitivity analyses using alternative distributions for PFS and OS yielded different results. It was observed that the base-case result was most sensitive to the extrapolation model adopted for OS in the nivolumab arm. If the generalised gamma distribution was chosen to extrapolate the long-term overall survival rate, the QALYs and LYs gained would decrease from 1.06 to 0.72 and from 1.51 to 0.96, respectively, for the nivolumab-treated patients (Table 3) . For the Markov model, in the nivolumab treatment group, if the generalised gamma distribution was selected to predict the long-term PFS, the total QALYs and LYs gained again reduced from 1.03 to 0.87 and from 1.33 to 1.11, respectively. However, if the log-logistic distribution was used to fit the post-progression survival data, an increase in the costs (A$108,631), QALYs (1.27) and LYs (1.67) was observed. In the docetaxel treatment group, the costs and benefits generated from the treatment were sensitive to the distribution employed to extrapolate post-progression survival. In particular, if the Weibull distribution was selected, costs (A$16,305), QALYs (0.50) and LYs (0.65) all decreased significantly in comparison to the base-case scenario (Table 3) . The Tornado diagram showed that the ICER was considerably driven by the cost of nivolumab, time horizon, duration of treatment with nivolumab, discount rate, utility of PD state, and management cost for the PF state, whereas the drug administration cost of nivolumab and utility of PF state had a very minimal impact on the ICER (Fig. 1) . Further, the sensitivity analysis adopting the utility weights recommended by NICE (utilities of PD 0.43 and PF 0.65, respectively) [22] generated a slightly higher ICER than the base case (A$235,169/QALY).
Probabilistic Sensitivity Analyses
For the Markov model, probabilistic sensitivity analyses incorporating distributions of key model parameters showed that the mean results based on 5000 simulations of the probabilistic model were very close to the base-case results for this population; for example, the ICER was A$220,029 versus A$215,989 per QALY (Table 3 ). The cost-effectiveness plane indicated that all 5000 iterations results from the PSA fell in the Northeast quadrant, suggesting that nivolumab was more effective but more expensive in all simulations (Fig. 2) . The cost-effectiveness acceptability curve showed that if the WTP/QALY threshold is greater than A$210,000, nivolumab becomes more likely to be the cost-effective treatment strategy (Fig. 3) . 
Discussion
Based on two economic models developed to assess the cost-effectiveness of nivolumab in treating patients with advanced or metastatic squamous NSCLC who progressed on or after platinum-based chemotherapy in comparison to docetaxel, unsurprisingly nivolumab was associated with both greater costs and benefits (i.e. QALYs and LYs) compared to existing treatment; the corresponding ICER was between A$198,862/QALY and A$220,029/QALY gained. Using the often-quoted willingness-to-pay per QALY threshold from PBAC (i.e. A$50,000/QALY) in Australia, the use of nivolumab for this indication cannot be considered cost-effective. It was noted that the benefits associated with nivolumab were more about prolonging the overall survival by affecting the time spent in the progression-free health state, which is the key value of nivolumab.
It might be argued that, in the past, PBAC has recommended public subsidy of oncology drugs that have an ICER ranging from A$105,000/QALY to A$200,000/QALY [23] . The recommendation of medications with high ICERs suggests that besides the ICER, other factors have also impacted on the decision. These factors would include the unmet clinical need, priority of the disease, the intervention's place in therapy, and the budget impact. It is not common from the PBAC's point of view to not recommend a new drug due to significant opportunity cost [24] . It is expected that the manufacturer of nivolumab will put in a resubmission for the PBAC's consideration given the latest decision made by the PBAC was to defer its listing. The ICER suggested by the Economic Sub-Committee to the PBAC was in a range between A$105,000/QALY and A$200,000/QALY, and our results are very close to this range [12] . In fact, the PBAC also requested that the Department of Health hold discussions with the manufacturer in order to develop a proposal for a Managed Entry Scheme (MES) (i.e. a mechanism to address the uncertainty over the size of the additional clinical benefit while providing early access to patients for whom there is a high clinical need). Further, the manufacturer also proposed the Risk Sharing Arrangements [12] , where the published price would be greater than the effective price; therefore, the current study did not adopt the price of nivolumab published on the website (besides it being for another indication).
It was projected that lung cancer was the most common cause of death from cancer in 2017 in Australia, more than that from colorectal, prostate, breast and pancreatic cancer [2] . Furthermore, the survival prognosis in lung cancer has not improved significantly compared to other cancers. For instance, breast and colon cancer has seen a 15% increase in the 5-year survival rate compared to decades ago, whereas for lung cancer, there was only an 6% increase [2, 25] . Despite a range of advanced therapeutic intervention strategies, the average survival across all disease stages for NSCLC was only 15% [26] . Considering the poor prognosis for patients with advanced NSCLC, there is a significant clinical need for treatment to effectively increase survival for this population.
The discrepancy in our results between PS and Markov models is worth noting. Consistent with previous reports, analyses based on a PS model have an inherent bias in favour of interventions that impact disease progression, not within health state mortality (i.e. the improvement in overall survival is driven by the PFS) since the PS model does not permit analysis of the post-progression period separately from the progression-free period [13] . Echoing their findings, the ICER produced by the Markov model was indeed higher than the PS model in our current study (A$220,029/ QALY vs. A$198,862/QALY). Another economic evaluation investigated the cost-effectiveness of nivolumab in the same population for Canadian patients, but reported that the PS (CA$151,560/QALY) and Markov (CA$152,229/ QALY) models generated highly consistent results [7] . As the time-dependent transition probabilities were different between the Canadian and the current studies (due to the difference in distributions used to extrapolate the treatment effect observed over the trial duration) in addition to the inconsistency of the time horizons modelled, it is difficult to ascertain the underlying causes for the differences.
The sensitivity analysis showed that the base-case ICER from both PS and Markov models was considerably sensitive to the distributions selected to extrapolate the Kaplan-Meier curve observed over the trial duration. Although the assessment of model fit such as AIC and BIC are widely used, they only provide information about the fit to the observed data, while often discounting for some measure of model complexity and not on how reasonable the extrapolation looks [27] . In addition, with a competing risk scenario, such as transition from PF to PD/death, it is not appropriate to make the choice based on AIC, therefore the visual assessment remains the only option. In the current study, the practice recommended by NICE and the study by Williams et al. [27] was adhered to in order to choose the most appropriate distribution. Moreover, extensive sensitivity analyses adopting alternative distributions were performed to examine the variation in the base-case results. It may be reassuring to a certain extent that the predicted OS curve derived from Markov model fits well to the observed plus extrapolated OS curve, which indicated that the Markov model was likely to produce reasonable estimations over time (Supplementary Fig. 15 ). This is the first published study to evaluate the cost-effectiveness of nivolumab in squamous NSCLC in Australia. The three-state model structure has been extensively validated and applied in a number of health technology assessments on oncology medications. Two modelling approaches, PS and Markov model, were adopted to compare and validate the results with each other. Additionally, the utilities values for the PF and PD health states were sourced from a pivotal trial evaluating the clinical efficacy and safety of nivolumab in the same cohort of patients (i.e. it has a plausibly higher face validity). The predicted results from the Markov model are also similar to the results observed in a longer term openlabel study [28] . Specifically, for the nivolumab arm, the OS and PFS were 26% and 13%, respectively, in our extrapolation versus 29% and 12% in the study by Horn et al. in 2017 [28] . The comparator used in the current study was also considered appropriate by the decision-makers.
Several limitations of the study need to be mentioned: First of all, the long-term PFS and OS required extrapolation on the basis of fitting curves to the reconstructed IPD. The reconstructed IPD is only a maximum approximation of the true trial data, while the method used to reconstruct IPD has a reasonable accuracy [17] ; extensive sensitivity analyses were conducted to explore this uncertainty. Second, the utility weights were sourced from the study based on the Canadian EQ-5D tariff. However, the PBAC-reviewed utility weights were tested in the sensitivity analysis. Third, the present study only captured the treatment benefits from a traditional healthcare system perspective (i.e. QALY is the outcome measure), while wider societal benefits including the option of value of treatment, value cancer patients place on durable survival (value of hope), etc. [29] , were not factored into the benefit measurement. Fourth, we were not able to capture the time that each participant stayed in each health state due to the design of the model (Markov cohort). Lastly, given the favourable profile of adverse events (AEs) observed in the nivolumab arm, the omission of the disutilities associated with AEs might cause an underestimation of the treatment benefits, thus leading to potential overestimation of the ICER.
For patients with advanced or metastatic squamous NSCLC, nivolumab was associated with both greater costs and greater benefits (QALY and LY gains) compared to docetaxel, the current available treatment for this patient population. Based on the Markov model, the incremental cost per additional QALY gain was A$220,029 and the incremental cost per additional LY gain was A$193,459. The PSA by incorporating distributions of key model parameters yielded similar results to the base-case scenario. The base-case results were fairly sensitive to the distribution utilised to extrapolate the PFS and OS beyond trial duration. Using the usually quoted WTP/QALY threshold in Australia, the use of nivolumab for patients with advanced or metastatic squamous NSCLC cannot be considered cost-effective; however, it might be funded publicly by special arrangements given the unmet clinical need for patients in Australia.
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